ALung closes $36m Series C

Artificial lung-like device developer ALung Technologies said today it closed a $36 million Series C financing round, with funds slated to support a US pivotal trial of its Hemolung respiratory assist system as it pursues FDA approval. The Pittsburgh, Penn.-based company is developing the Hemolung device, an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. The funding round was led by Royal Philips (NYSE:PHG) and UPMC and joined by Abiomed (NSDQ:ABMD), The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures and Riverfront Ventures. “Since 2013, hundreds of patients with acute respiratory failure have been successfully treated with the Hemolung RAS outside of the United States. With this new financing, we will be able to conduct our US-based clinical trial, an important step towards obtaining FDA approval and making our device available to patients in the United States. We are grateful to Philips, UPMC, and our many other investors for their commitment to ALung and the numerous patients who stand to benefit from our technology,” ALung CEO &chair Peter DeComo said in a press release. As part of the funding round, Philips patient care &monitoring systems chief medical officer Dr. Adam Seiver and UPMC’s Jeanne Cunicelli will join ALung’s board of directors, the com...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Respiratory Abiomed Inc. ALung Technologies Inc. Royal Philips Source Type: news

Related Links:

Artem Sokolov1, Stephanie Ashenden2,3, Nil Sahin4,5, Richard Lewis2, Nurdan Erdem4, Elif Ozaltan4, Andreas Bender2, Frederick P. Roth5,6,7 and Murat Cokol1,4,5,8* 1Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, United States 2Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Cambridge, United Kingdom 3Discovery Sciences, IMed Biotech Unit, AstraZeneca R&D, Cambridge, United Kingdom 4Faculty of Engineering and Natural Sciences, Sabanc─▒ University, Istanbul, Turkey 5Donnelly Centre, University of Toronto, Toronto, ON, Canada 6Department of Molecular Gene...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractPrimary graft dysfunction (PGD) remains the leading cause of early mortality post-heart transplantation. Despite improvements in mechanical circulatory support and critical care measures, the rate of PGD remains significant. A recent consensus statement by the International Society of Heart and Lung Transplantation (ISHLT) has formulated a definition for PGD. Five years on, we look at current concepts and future directions of PGD in the current era of transplantation.
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Long-term survival after lung transplantation remains limited by the development of chronic lung allograft dysfunction (CLAD), which affects approximately 50% of lung recipients by 5 years post-transplant.1 Given the lack of a proven therapy once CLAD is diagnosed, risk factor mitigation is a key preventive strategy. The principal risk factor for CLAD is A-grade acute cellular rejection (ACR). A-grade ACR is diagnosed by transbronchial biopsy (TBB), exhibiting perivascular mononuclear cell infiltrates that extend into the interstitium with higher grade rejection.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: EDITORIAL Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
A Nova Scotia woman has received a double lung transplant just months after she thought the financial burden of the procedure would force her into palliative care.
Source: CBC | Health - Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news
Authors: Feng M, Yang X, He Y Abstract AIM: Present study was performed to explore the effects of bronchial provocation test (BPT) and bronchial dilation test (BDT) for the diagnosis of lung diseases. METHODS: BPT and BDT results were respectively detected by methacholine and albuterol in patients with different lung diseases and non-lung diseases. BPT and BDT indexes including exhaled nitric oxide (ENO), forced expiratory volume of first minute (FEV1), forced vital capacity (FVC), diffusion of carbon monoxide in the lungs (DLCO) and eosinophilia (EOS) were compared by t-test between different groups. RESUL...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
CONCLUSION: These new recommendations, close to French practices, help clinicians to find the right time for referral of patients to transplantation centers. This is crucial for the prognosis of lung transplantation. PMID: 31006579 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
More News: Clinical Trials | Funding | Hospitals | Lung Transplant | Respiratory Medicine | Science